Intersect ENT Inc. (NASDAQ:XENT) has been assigned an average rating of “Buy” from the eleven ratings firms that are currently covering the firm. Four equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.80.

A number of equities research analysts have weighed in on the company. Canaccord Genuity restated a “buy” rating and set a $20.00 price objective on shares of Intersect ENT in a research note on Thursday, August 4th. Wedbush restated an “outperform” rating and set a $25.00 price objective on shares of Intersect ENT in a research note on Wednesday, August 3rd. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. JPMorgan Chase & Co. lowered Intersect ENT from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $25.00 to $16.00 in a research note on Wednesday, November 2nd. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $21.00 price objective on shares of Intersect ENT in a research note on Friday, August 26th.

Shares of Intersect ENT (NASDAQ:XENT) opened at 12.70 on Tuesday. The stock’s market cap is $362.76 million. The stock’s 50 day moving average price is $15.10 and its 200 day moving average price is $14.89. Intersect ENT has a 1-year low of $7.65 and a 1-year high of $23.00.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%. The business earned $18.50 million during the quarter, compared to analyst estimates of $17.80 million. During the same quarter last year, the firm earned ($0.35) earnings per share. The company’s revenue for the quarter was up 30.3% compared to the same quarter last year. On average, equities research analysts anticipate that Intersect ENT will post ($0.92) EPS for the current fiscal year.

In other news, VP Amy Wolbeck sold 28,664 shares of Intersect ENT stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $15.83, for a total value of $453,751.12. Following the completion of the transaction, the vice president now owns 18,076 shares in the company, valued at approximately $286,143.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP James Stambaugh sold 4,000 shares of Intersect ENT stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $16.00, for a total value of $64,000.00. Following the completion of the transaction, the vice president now owns 23,700 shares of the company’s stock, valued at approximately $379,200. The disclosure for this sale can be found here. 13.90% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Granahan Investment Management Inc. MA increased its stake in shares of Intersect ENT by 28.0% in the first quarter. Granahan Investment Management Inc. MA now owns 549,321 shares of the company’s stock valued at $10,437,000 after buying an additional 120,286 shares during the period. California State Teachers Retirement System increased its stake in shares of Intersect ENT by 53.5% in the second quarter. California State Teachers Retirement System now owns 53,490 shares of the company’s stock valued at $692,000 after buying an additional 18,639 shares during the period. Granite Point Capital Management L.P. bought a new stake in shares of Intersect ENT during the second quarter valued at about $1,053,000. Emerald Acquisition Ltd. bought a new stake in shares of Intersect ENT during the second quarter valued at about $552,000. Finally, Kornitzer Capital Management Inc. KS increased its stake in shares of Intersect ENT by 32.7% in the second quarter. Kornitzer Capital Management Inc. KS now owns 169,100 shares of the company’s stock valued at $2,186,000 after buying an additional 41,700 shares during the period. 77.76% of the stock is currently owned by institutional investors and hedge funds.

About Intersect ENT

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

5 Day Chart for NASDAQ:XENT

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.